{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:13:31Z","timestamp":1792602811441,"version":"4.5.0"},"reference-count":238,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T00:00:00Z","timestamp":1662249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Although pancreatic cancer (PC) was considered in the past an orphan cancer type due to its low incidence, it may become in the future one of the leading causes of cancer death. Pancreatic ductal adenocarcinoma (PDAC) is the most frequent type of PC, being a highly aggressive malignancy and having a 5-year survival rate of less than 10%. Non-modifiable (family history, age, genetic susceptibility) and modifiable (smoking, alcohol, acute and chronic pancreatitis, diabetes mellitus, intestinal microbiota) risk factors are involved in PC pathogenesis. Chronic inflammation induced by various factors plays crucial roles in PC development from initiation to metastasis. In multiple malignant conditions such as PC, cytokines, chemokines, and growth factors activate the class I phosphoinositide 3-kinase (PI3K)\/protein kinase B (AKT)\/mammalian target of rapamycin (mTOR) (PI3K\/AKT\/mTOR) signaling pathway, which plays key roles in cell growth, survival, proliferation, metabolism, and motility. Currently, mTOR, AKT, and PI3K inhibitors are used in clinical studies. Moreover, PI3K\/mTOR dual inhibitors are being tested in vitro and in vivo with promising results for PC patients. The main aim of this review is to present PC incidence, risk factors, tumor microenvironment development, and PI3K\/AKT\/mTOR dysregulation and inhibitors used in clinical, in vivo, and in vitro studies.<\/jats:p>","DOI":"10.3390\/ijms231710132","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T05:17:23Z","timestamp":1662441443000},"page":"10132","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":140,"title":["Targeting PI3K\/AKT\/mTOR Signaling Pathway in Pancreatic Cancer: From Molecular to Clinical Aspects"],"prefix":"10.3390","volume":"23","author":[{"given":"Silviu","family":"Stanciu","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Dr. Carol Davila Central Military Emergency University Hospital, 051075 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9829-5035","authenticated-orcid":false,"given":"Florentina","family":"Ionita-Radu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Dr. Carol Davila Central Military Emergency University Hospital, 051075 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantin","family":"Stefani","sequence":"additional","affiliation":[{"name":"Department of Family Medicine and Clinical Base, Dr. Carol Davila Central Military Emergency University Hospital, 051075 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Miricescu","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Dental Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iulia-Ioana","family":"Stanescu-Spinu","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Dental Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Greabu","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Dental Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4345-282X","authenticated-orcid":false,"given":"Alexandra","family":"Ripszky Totan","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Dental Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Jinga","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Dr. Carol Davila Central Military Emergency University Hospital, 051075 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.3748\/wjg.v24.i43.4846","article-title":"Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes","volume":"21","author":"McGuigan","year":"2018","journal-title":"World. J. Gastroenterol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/14728214.2017.1293648","article-title":"Emerging protein kinase inhibitors for treating pancreatic cancer","volume":"22","author":"Furuse","year":"2017","journal-title":"Expert. Opin. Emerg. Drugs."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bpg.2005.10.001","article-title":"Epidemiology and risk factors for pancreatic cancer","volume":"20","author":"Lowenfels","year":"2006","journal-title":"Best. Pract. Res. Clin. Gastroenterol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.bpg.2017.09.001","article-title":"Tobacco and alcohol as risk factors for pancreatic cancer","volume":"31","author":"Korc","year":"2017","journal-title":"Best. Pract. Res. Clin. Gastroenterol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"9694","DOI":"10.3748\/wjg.v22.i44.9694","article-title":"Epidemiology of pancreatic cancer","volume":"28","author":"Ilic","year":"2016","journal-title":"World. J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.trecan.2018.04.001","article-title":"Immunotherapy and prevention of pancreatic cancer","volume":"4","author":"Morrison","year":"2018","journal-title":"Trends Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"826","DOI":"10.31128\/AJGP-06-19-4957","article-title":"Pancreatic cancer: An update on diagnosis and management","volume":"48","author":"Loveday","year":"2019","journal-title":"Aust. J. Gen. Pract."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s00595-020-02028-0","article-title":"Pancreatic cancer treatment: Better, but a long way to go","volume":"50","author":"Torphy","year":"2020","journal-title":"Surg. Today"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5619","DOI":"10.7314\/APJCP.2015.16.14.5619","article-title":"Pancreatic cancer: Pathogenesis and Diagnosis","volume":"16","author":"Goral","year":"2015","journal-title":"Asian. Pac. J. Cancer Prev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1042\/BST20170521","article-title":"RAS in pancreatic cancer","volume":"30","author":"Lanfredini","year":"2019","journal-title":"Biochem. Soc. Trans."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1002\/cncr.23648","article-title":"Inherited pancreatic endocrine tumor syndromes: Advances in molecular pathogenesis, diagnosis, management, and controversies","volume":"1","author":"Jensen","year":"2008","journal-title":"Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/ags3.12459","article-title":"Roles of the nervous system in pancreatic cancer","volume":"29","author":"Wakiya","year":"2021","journal-title":"Ann. Gastroenterol. Surg."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1159\/000503721","article-title":"neuroendocrine neoplasms of the small bowel and pancreas","volume":"110","author":"Clift","year":"2020","journal-title":"Neuroendocrinology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"264","DOI":"10.4161\/sgtp.2.5.17367","article-title":"Ras, PI3K and senescence","volume":"2","author":"Kennedy","year":"2011","journal-title":"Small GTPase"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.3748\/wjg.v17.i24.2897","article-title":"Molecular biology of pancreatic cancer","volume":"28","author":"Zavoral","year":"2011","journal-title":"World. J. Gastroenterol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.pan.2019.11.006","article-title":"Differences between KC and KPC pancreatic ductal adenocarcinoma mice models, in terms of their modeling biology and their clinical relevance","volume":"20","author":"Ariston","year":"2020","journal-title":"Pancreatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"173","DOI":"10.4251\/wjgo.v12.i2.173","article-title":"Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy","volume":"15","author":"Sarantis","year":"2020","journal-title":"World. J. Gastrointest. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S2468-1253(19)30416-9","article-title":"Early detection of pancreatic cancer","volume":"5","author":"Pereira","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"562505","DOI":"10.3389\/fendo.2020.562505","article-title":"mTOR pathway in gastroenteropancreatic neuroendocrine numor (GEP-NETs)","volume":"16","author":"Zanini","year":"2020","journal-title":"Front. Endocrinol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1024\/0040-5930\/a001317","article-title":"Pancreatic cancer","volume":"78","author":"Galli","year":"2021","journal-title":"Ther. Umsch."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.soc.2021.06.002","article-title":"Inherited pancreatic cancer syndromes and high-risk screening","volume":"30","author":"Biller","year":"2021","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/MOG.0000000000000663","article-title":"Early detection of pancreatic cancer","volume":"36","author":"Garg","year":"2020","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2021.06.027","article-title":"Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis","volume":"1","author":"Cai","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Ushio, J., Kanno, A., Ikeda, E., Ando, K., Nagai, H., Miwata, T., Kawasaki, Y., Tada, Y., Yokoyama, K., and Numao, N. (2021). Pancreatic ductal adenocarcinoma: Epidemiology and risk factors. Diagnostics, 20.","DOI":"10.3390\/diagnostics11030562"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1615\/CritRevOncog.2019031637","article-title":"Familial pancreatic cancer: A critical review","volume":"24","author":"Rahman","year":"2019","journal-title":"Crit. Rev. Oncog."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"27","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1188\/19.CJON.579-582","article-title":"Hereditary pancreatic cancer syndromes: Providing care to at-risk families","volume":"1","author":"King","year":"2019","journal-title":"Clin. J. Oncol. Nurs."},{"key":"ref_28","first-page":"S29","article-title":"Precancerous conditions and risk factors for pancreatic and bile duct cancer","volume":"26","year":"2013","journal-title":"Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/j.lpm.2019.02.030","article-title":"Epidemiology and burden of pancreatic cancer","volume":"48","author":"Maisonneuve","year":"2019","journal-title":"Presse. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.canlet.2020.04.022","article-title":"Updated risk factors to inform early pancreatic cancer screening and identify high risk patients","volume":"10","author":"Principe","year":"2020","journal-title":"Cancer. Lett."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"16022","DOI":"10.1038\/nrdp.2016.22","article-title":"Pancreatic cancer","volume":"21","author":"Kleeff","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41571-019-0281-6","article-title":"From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer","volume":"17","author":"Hidalgo","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2174\/187152011795677382","article-title":"Targeting phosphoinositide 3-kinase pathways in pancreatic cancer--from molecular signalling to clinical trials","volume":"11","author":"Falasca","year":"2011","journal-title":"Anticancer Agent. Med. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"11182","DOI":"10.3748\/wjg.v20.i32.11182","article-title":"Pancreatic ductal adenocarcinoma: Risk factors, screening, and early detection","volume":"28","author":"Becker","year":"2014","journal-title":"World. J. Gastroenterol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/S1470-2045(19)30795-8","article-title":"Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: A bright future","volume":"21","author":"Christenson","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_36","first-page":"407","article-title":"Kras as a key oncogene and therapeutic target in pancreatic cancer","volume":"21","author":"Collins","year":"2014","journal-title":"Front. Physiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/j.seminoncol.2021.02.003","article-title":"KRAS mutation in pancreatic cancer","volume":"48","author":"Luo","year":"2021","journal-title":"Semin Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"13563","DOI":"10.1038\/srep13563","article-title":"Clinicopathological significance of CDKN2A promoter hypermethylation frequency with pancreatic cancer","volume":"4","author":"Tang","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1533033820962117","DOI":"10.1177\/1533033820962117","article-title":"Pancreatic Cancer: A review of risk factors, diagnosis, and treatment","volume":"19","author":"Zhao","year":"2020","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.canlet.2016.07.022","article-title":"Modifiable and non modifiable risk factors for pancreatic cancer: A review","volume":"10","author":"Midha","year":"2016","journal-title":"Cancer. Lett."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ijsu.2018.02.058","article-title":"Risk factor, early diagnosis and overall survival on outcome of association between pancreatic cancer and diabetes mellitus: Changes and advances, a review","volume":"52","author":"Khadka","year":"2018","journal-title":"Int. J. Surg."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1080\/14737140.2019.1642109","article-title":"Exploring the link between diabetes and pancreatic cancer","volume":"19","author":"Pizzato","year":"2019","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/978-1-4614-5441-0_18","article-title":"Pancreatic cancer and diabetes","volume":"771","author":"Morrison","year":"2012","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nutres.2017.12.001","article-title":"Pancreatic cancer: A critical review of dietary risk","volume":"52","author":"Salem","year":"2018","journal-title":"Nutr. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1159\/000323933","article-title":"Environmental risk factors for chronic pancreatitis and pancreatic cancer","volume":"29","author":"Nitsche","year":"2011","journal-title":"Dig. Dis."},{"key":"ref_46","first-page":"1429","article-title":"Possibility of pancreatic cancer chemoprevention by anti-inflammatory\/anti-diabetic\/anti-dyslipidemic drugs","volume":"48","author":"Takahashi","year":"2021","journal-title":"Cancer Chemother."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Lu, P.Y., Shu, L., Shen, S.S., Chen, X.J., and Zhang, X.Y. (2017). Dietary patterns and pancreatic cancer risk: A meta-analysis. Nutrients, 5.","DOI":"10.3390\/nu9010038"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Pang, Y., Kartsonaki, C., Turnbull, I., Guo, Y., Yang, L., Bian, Z., Chen, Y., Millwood, I.Y., Bragg, F., and Gong, W. (2018). Metabolic and lifestyle risk factors for acute pancreatitis in Chinese adults: A prospective cohort study of 0.5 million people. PLoS Med., 15.","DOI":"10.1371\/journal.pmed.1002618"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"7988","DOI":"10.3748\/wjg.v21.i26.7988","article-title":"Current status and progress of pancreatic cancer in China","volume":"14","author":"Lin","year":"2015","journal-title":"World. J. Gastroenterol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.suronc.2014.02.003","article-title":"Obesity and pancreatic cancer","volume":"23","author":"Preziosi","year":"2014","journal-title":"Surg. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.pan.2015.01.013","article-title":"Early onset pancreatic cancer: Risk factors, presentation and outcome","volume":"15","author":"Piciucchi","year":"2015","journal-title":"Pancreatology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.canep.2018.12.001","article-title":"A systematic assessment of statistics, risk factors, and underlying features involved in pancreatic cancer","volume":"58","author":"Aier","year":"2019","journal-title":"Cancer. Epidemiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/MOG.0000000000000377","article-title":"Chronic pancreatitis","volume":"33","author":"Yang","year":"2017","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1053\/j.gastro.2013.01.068","article-title":"The epidemiology of pancreatitis and pancreatic cancer","volume":"144","author":"Yadav","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/ajg.2017.218","article-title":"Chronic pancreatitis and pancreatic cancer risk: A systematic review and meta-analysis","volume":"112","author":"Mortensen","year":"2017","journal-title":"Am. J. Gastroenterol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.pop.2017.07.004","article-title":"Pancreatitis and pancreatic cancer","volume":"44","author":"Walling","year":"2017","journal-title":"Prim. Care"},{"key":"ref_57","first-page":"47","article-title":"Assessment of severity of acute pancreatitis over time","volume":"58","author":"Cofaru","year":"2020","journal-title":"Rom. J. Intern. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1440-1746.2011.07013.x","article-title":"Epidemiology, risk factors, and the promotion of pancreatic cancer: Role of the stellate cell","volume":"27","author":"Pandol","year":"2012","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.dld.2017.07.001","article-title":"Incidence of and risk factors for pancreatic cancer in chronic pancreatitis: A cohort of 1656 patients","volume":"49","author":"Hao","year":"2017","journal-title":"Dig. Liver. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.cell.2019.07.008","article-title":"Tumor microbiome diversity and composition influence pancreatic cancer outcomes","volume":"8","author":"Riquelme","year":"2019","journal-title":"Cell"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12943-019-1008-0","article-title":"The microbiota and microbiome in pancreatic cancer: More influential than expected","volume":"20","author":"Wei","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.3748\/wjg.v27.i27.4298","article-title":"Pancreatic cancer: A review of epidemiology, trend, and risk factors","volume":"21","author":"Hu","year":"2021","journal-title":"World. J. Gastroenterol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"103","DOI":"10.5334\/aogh.2463","article-title":"Using the risk factors of pancreatic cancer and their interactions in cancer screening: A case-control study in Shanghai, China","volume":"11","author":"Bo","year":"2019","journal-title":"Ann. Glob. Health."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2188\/jea.JE20140148","article-title":"Risk factors for pancreatic cancer in China: A multicenter case-control study","volume":"26","author":"Zheng","year":"2016","journal-title":"J. Epidemiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s11739-018-1795-0","article-title":"Pancreatic cancer: Risk and preventive factors","volume":"13","author":"Licata","year":"2018","journal-title":"Intern. Emerg. Med."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Zheng, Z., Chen, Y., Tan, C., Ke, N., Du, B., and Liu, X. (2019). Risk of pancreatic cancer in patients undergoing surgery for chronic pancreatitis. BMC Surg., 8.","DOI":"10.1186\/s12893-019-0537-1"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S2468-1253(16)30106-6","article-title":"Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer","volume":"1","author":"Hart","year":"2016","journal-title":"Lancet. Gastroenterol. Hepatol."},{"key":"ref_68","first-page":"1073274821989320","article-title":"Risk factors of pancreatic cancer in Vietnam: A matched case-control hospital-based study","volume":"28","author":"Nguyen","year":"2021","journal-title":"Cancer. Control."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/MPA.0000000000001016","article-title":"Understanding the pathophysiology of psychological distress and pancreatic cancer: A systematic review","volume":"47","author":"Bettison","year":"2018","journal-title":"Pancreas"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/mc.20779","article-title":"Occupational risk factors and pancreatic cancer: A review of recent findings","volume":"51","author":"Andreotti","year":"2012","journal-title":"Mol Carcinog."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1007\/s10067-019-04660-9","article-title":"Risk of pancreatic cancer in patients with systemic lupus erythematosus: A meta-analysis","volume":"38","author":"Seo","year":"2019","journal-title":"Clin. Rheumatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"227","DOI":"10.4149\/neo_2020_200706N699","article-title":"Risk factors of pancreatic cancer and their possible uses in diagnostics","volume":"68","author":"Lang","year":"2021","journal-title":"Neoplasma"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"7864","DOI":"10.3748\/wjg.v20.i24.7864","article-title":"Imaging diagnosis of pancreatic cancer: A state-of-the-art review","volume":"28","author":"Lee","year":"2014","journal-title":"World. J. Gastroenterol."},{"key":"ref_74","first-page":"E583","article-title":"Pancreatic cancer related pain: Review of pathophysiology and intrathecal drug delivery systems for pain management","volume":"24","author":"Carvajal","year":"2021","journal-title":"Pain Physician"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e971","DOI":"10.1002\/onco.13796","article-title":"Pancreas cancer-associated pain management","volume":"26","author":"Coveler","year":"2021","journal-title":"Oncologist"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.21873\/anticanres.14133","article-title":"Pathogenesis and treatment of pancreatic cancer related pain","volume":"40","author":"Lohse","year":"2020","journal-title":"Anticancer. Res."},{"key":"ref_77","first-page":"322","article-title":"Pancreatic Cancer","volume":"8","author":"Moore","year":"2019","journal-title":"JAMA"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/jso.24623","article-title":"Current and future therapies for advanced pancreatic cancer","volume":"116","author":"Gupta","year":"2017","journal-title":"J. Surg. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nrgastro.2013.120","article-title":"Mucins in pancreatic cancer and its microenvironment","volume":"10","author":"Kaur","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1152\/physrev.00042.2019","article-title":"Microenvironmental determinants of pancreatic cancer","volume":"1","author":"Hessmann","year":"2020","journal-title":"Physiol. Rev."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41575-018-0005-x","article-title":"Therapeutic developments in pancreatic cancer: Current and future perspectives","volume":"15","author":"Neoptolemos","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"11216","DOI":"10.3748\/wjg.v20.i32.11216","article-title":"Pancreatic cancer and its stroma: A conspiracy theory","volume":"28","author":"Xu","year":"2014","journal-title":"World. J. Gastroenterol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"19","DOI":"10.21037\/cco.2019.04.02","article-title":"Inflammation and development of pancreatic ductal adenocarcinoma","volume":"8","author":"Shi","year":"2019","journal-title":"Chin. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"5372","DOI":"10.1002\/jcp.27372","article-title":"Melatonin and pancreatic cancer: Current knowledge and future perspectives","volume":"234","author":"Tamtaji","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Orlacchio, A., and Mazzone, P. (2021). The Role of Toll-like Receptors (TLRs) mediated inflammation in pancreatic cancer pathophysiology. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms222312743"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"105595","DOI":"10.1016\/j.phrs.2021.105595","article-title":"Pancreatitis initiated pancreatic ductal adenocarcinoma: Pathophysiology explaining clinical evidence","volume":"168","author":"Tao","year":"2021","journal-title":"Pharmacol. Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00424-017-1968-0","article-title":"Biology of pancreatic stellate cells-more than just pancreatic cancer","volume":"469","author":"Ferdek","year":"2017","journal-title":"Pflugers Arch."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"152685","DOI":"10.1016\/j.prp.2019.152685","article-title":"SPARC expression in desmoplastic and non desmoplastic pancreatic carcinoma and cholangiocarcinoma","volume":"215","author":"Khetan","year":"2019","journal-title":"Pathol. Res. Pract."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ccell.2021.02.007","article-title":"Type I collagen deletion in \u03b1SMA + myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer","volume":"12","author":"Chen","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1146\/annurev-physiol-021014-071727","article-title":"Regeneration and repair of the exocrine pancreas","volume":"77","author":"Murtaugh","year":"2015","journal-title":"Ann. Rev. Physiol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1080\/15548627.2020.1847462","article-title":"Regulation and function of autophagy in pancreatic cancer","volume":"17","author":"Li","year":"2021","journal-title":"Autophagy"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.gtc.2019.04.008","article-title":"The microbiota and pancreatic cancer","volume":"48","year":"2019","journal-title":"Gastroenterol. Clin. North. Am."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/labinvest.2017.127","article-title":"Experimental models of pancreatic cancer desmoplasia","volume":"98","author":"Suklabaidya","year":"2018","journal-title":"Lab. Investig."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Kaps, L., and Schuppan, D. (2020). Targeting cancer associated fibroblasts in liver fibrosis and liver cancer using nanocarriers. Cells, 3.","DOI":"10.3390\/cells9092027"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.joca.2020.02.027","article-title":"The PI3K\/AKT\/mTOR signaling pathway in osteoarthritis: A narrative review","volume":"28","author":"Sun","year":"2020","journal-title":"Osteoarthr. Cartil."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/jdi.13727","article-title":"Non-coding RNAs underlying the pathophysiological links between type 2 diabetes and pancreatic cancer: A systematic review","volume":"13","author":"Dehghanian","year":"2022","journal-title":"J. Diabetes. Investig."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"102655","DOI":"10.1016\/j.ebiom.2020.102655","article-title":"Recent insights into the biology of pancreatic cancer","volume":"53","author":"Yao","year":"2020","journal-title":"EBioMedicine"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jss.2011.09.020","article-title":"Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progression","volume":"173","author":"Krantz","year":"2012","journal-title":"J. Surg. Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3892\/or.2015.4357","article-title":"The pancreatic cancer secreted REG4 promotes macrophage polarization to M2 through EGFR\/AKT\/CREB pathway","volume":"35","author":"Ma","year":"2016","journal-title":"Oncol. Rep."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/MPA.0000000000000974","article-title":"Obesity and pancreatic cancer: Overview of epidemiology and potential prevention by weight loss","volume":"47","author":"Xu","year":"2018","journal-title":"Pancreas"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Batista, I.A., and Melo, S.A. (2019). Exosomes and the future of immunotherapy in pancreatic cancer. Int. J. Mol. Sci., 29.","DOI":"10.3390\/ijms20030567"},{"key":"ref_102","first-page":"203","article-title":"Identification and screening of individuals at increased risk for pancreatic cancer with emphasis on known environmental and genetic factors and hereditary syndromes","volume":"5","author":"Chu","year":"2010","journal-title":"JOP"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/MPA.0000000000001066","article-title":"A therapeutic strategy for resectable pancreatic cancer based on risk factors of early recurrence","volume":"47","author":"Kurahara","year":"2018","journal-title":"Pancreas"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.7150\/ijbs.60115","article-title":"N6-methyladenosine (m6A) in pancreatic cancer: Regulatory mechanisms and future direction","volume":"4","author":"Li","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Nepstad, I., Hatfield, K.J., Gr\u00f8nnings\u00e6ter, I.S., and Reikvam, H. (2020). The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21082907"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.tcb.2015.06.002","article-title":"Regulation of mTORC1 by PI3K signaling","volume":"25","author":"Dibble","year":"2015","journal-title":"Trends Cell Biol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.gene.2019.02.076","article-title":"The relation between PI3K\/AKT signalling pathway and cancer","volume":"25","author":"Noorolyai","year":"2019","journal-title":"Gene"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"105067","DOI":"10.1016\/j.neuint.2021.105067","article-title":"Targeting PI3K-AKT\/mTOR signaling in the prevention of autism","volume":"147","author":"Sharma","year":"2021","journal-title":"Neurochem. Int."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.7150\/ijbs.27173","article-title":"The PI3K\/AKT pathway in obesity and type 2 diabetes","volume":"6","author":"Huang","year":"2018","journal-title":"Int. J. Biol. Sci."},{"key":"ref_110","first-page":"783","article-title":"PI3K\/Akt signaling transduction pathway, erythropoiesis and glycolysis in hypoxia (Review)","volume":"19","author":"Xie","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/1759-7714.13328","article-title":"Targeting the PI3K\/Akt\/mTOR pathway in non-small cell lung cancer (NSCLC)","volume":"11","author":"Tan","year":"2020","journal-title":"Thorac. Cancer"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Mehra, S., Deshpande, N., and Nagathihalli, N. (2021). Targeting PI3K pathway in pancreatic ductal adenocarcinoma: Rationale and progress. Cancers, 2.","DOI":"10.3390\/cancers13174434"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1002\/med.21802","article-title":"Pharmaceuticals targeting signaling pathways of endometriosis as potential new medical treatment: A review","volume":"41","author":"Hung","year":"2021","journal-title":"Med. Res. Rev."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2174\/156800908784293659","article-title":"The PTEN\/PI3K\/AKT signalling pathway in cancer, therapeutic implications","volume":"8","author":"Carnero","year":"2008","journal-title":"Curr. Cancer Drug. Targets"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1002\/jcp.27262","article-title":"PI3k\/AKT signaling pathway: Erythropoiesis and beyond","volume":"234","author":"Jafari","year":"2019","journal-title":"J. Cell Physiol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12964-019-0450-3","article-title":"Distinct functions of AKT isoforms in breast cancer: A comprehensive review","volume":"21","author":"Hinz","year":"2019","journal-title":"Cell Commun. Signal"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e00031-20","DOI":"10.1128\/MCB.00031-20","article-title":"AKT1 regulates endoplasmic reticulum stress and mediates the adaptive response of pancreatic \u03b2 Cells","volume":"14","author":"Peng","year":"2020","journal-title":"Mol. Cell. Biol."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"De Santis, M.C., Sala, V., Martini, M., Ferrero, G.B., and Hirsch, E. (2017). PI3K Signaling in Tissue hyper-proliferation: From overgrowth syndromes to kidney cysts. Cancers, 29.","DOI":"10.3390\/cancers9040030"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/ncb839","article-title":"TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling","volume":"4","author":"Inoki","year":"2002","journal-title":"Nat. Cell Biol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1007\/s11010-021-04088-3","article-title":"Role of TSC1 in physiology and diseases","volume":"476","author":"Mallela","year":"2021","journal-title":"Mol. Cell. Biochem."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"R103","DOI":"10.1530\/JME-14-0220","article-title":"PI3K\/PTEN\/Akt and TSC\/mTOR signaling pathways, ovarian dysfunction, and infertility: An update","volume":"53","author":"Makker","year":"2014","journal-title":"J. Mol. Endocrinol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.14694\/EdBook_AM.2013.33.e395","article-title":"Targeting the PI3K\/AKT\/mTOR pathway: Biomarkers of success and tribulation","volume":"33","author":"Owonikoko","year":"2013","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"253","DOI":"10.5732\/cjc.013.10057","article-title":"Targeting the PI3K-AKT-mTOR signaling network in cancer","volume":"32","author":"Khan","year":"2013","journal-title":"Chin. J. Cancer"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Larsen, L.J., and M\u00f8ller, L.B. (2020). Crosstalk of hedgehog and mTORC1 pathways. Cells, 18.","DOI":"10.3390\/cells9102316"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"966","DOI":"10.3389\/fimmu.2018.00966","article-title":"Immune TOR-opathies,\" a novel disease entity in clinical immunology","volume":"9","author":"Jung","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1593\/neo.12532","article-title":"Targeting the mTOR-DEPTOR pathway by CRL E3 ubiquitin ligases: Therapeutic application","volume":"14","author":"Zhao","year":"2012","journal-title":"Neoplasia"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.2174\/0929867324666170206142658","article-title":"Targeting the Akt\/PI3K signaling pathway as a potential therapeutic strategy for the treatment of pancreatic Cancer","volume":"24","author":"Ebrahimi","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"107869","DOI":"10.1016\/j.pharmthera.2021.107869","article-title":"The diverse roles of circular RNAs in pancreatic cancer","volume":"226","author":"Chen","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1007\/s00018-015-1867-5","article-title":"Targeting PI3K\/AKT\/mTOR network for treatment of leukemia","volume":"72","author":"Bertacchini","year":"2015","journal-title":"Cell. Mol. Life. Sci."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.pharmthera.2013.12.004","article-title":"Molecular targets for cancer therapy in the PI3K\/AKT\/mTOR pathway","volume":"142","author":"Polivka","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"09468","DOI":"10.1016\/j.cellsig.2019.109468","article-title":"The PI3K\/Akt\/mTOR pathway in polycystic kidney disease: A complex interaction with polycystins and primary cilium","volume":"66","author":"Margaria","year":"2020","journal-title":"Cell Signal"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.2174\/092986710794182999","article-title":"PI3K\/AKT\/mTOR inhibitors in ovarian cancer","volume":"17","author":"Mazzoletti","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.gene.2015.08.060","article-title":"Role of mTOR in glioblastoma","volume":"10","author":"Duzgun","year":"2016","journal-title":"Gene"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.path.2020.05.007","article-title":"HER2 in colorectal carcinoma: Are we there yet?","volume":"13","author":"Nowak","year":"2020","journal-title":"Surg. Pathol. Clin."},{"key":"ref_135","first-page":"7163","article-title":"Everolimus inhibits breast cancer cell growth through PI3K\/AKT\/mTOR signaling pathway","volume":"17","author":"Du","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1158\/1541-7786.MCR-20-1066","article-title":"Emerging roles for AKT isoform preference in cancer progression pathways","volume":"19","author":"Degan","year":"2021","journal-title":"Mol. Cancer. Res."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jbior.2015.05.001","article-title":"Implication of PI3K\/Akt pathway in pancreatic cancer: When PI3K isoforms matter?","volume":"59","author":"Baer","year":"2015","journal-title":"Adv. Biol. Regul."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/CAD.0000000000000496","article-title":"Protein kinase B: Emerging mechanisms of isoform-specific regulation of cellular signaling in cancer","volume":"28","author":"Wadhwa","year":"2017","journal-title":"Anticancer Drugs"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.semcancer.2019.05.012","article-title":"Role of the PI3K\/AKT\/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance","volume":"59","author":"Ediriweera","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.semcancer.2019.07.009","article-title":"PI3K\/Akt\/mTOR inhibitors in cancer: At the bench and bedside","volume":"59","author":"Alzahrani","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ejmech.2016.01.012","article-title":"PI3K\/Akt\/mTOR and Ras\/Raf\/MEK\/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives","volume":"15","author":"Asati","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Selvarajoo, N., Stanslas, J., Islam, M.K., Sagineedu, S.R., Ho, K.L., and Lim, J.C.W. (2022). Pharmacological modulation of apoptosis and autophagy in the treatment of pancreatic cancer. Mini Rev. Med. Chem.","DOI":"10.2174\/1389557522666220324123605"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.4049\/jimmunol.1601515","article-title":"Akt signaling pathway in macrophage activation and M1\/M2 polarization","volume":"1","author":"Vergadi","year":"2017","journal-title":"J. Immunol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"336","DOI":"10.7150\/thno.7851","article-title":"PI3K-AKT-mTOR-signaling and beyond: The complex network in gastroenteropancreatic neuroendocrine neoplasms","volume":"29","author":"Briest","year":"2014","journal-title":"Theranostics"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"110133","DOI":"10.1016\/j.biopha.2020.110133","article-title":"The effect of ibrutinib on radiosensitivity in pancreatic cancer cells by targeting EGFR\/AKT\/mTOR signaling pathway","volume":"128","author":"Tan","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"R109","DOI":"10.1530\/ERC-18-0420","article-title":"Resistance to targeted treatment of gastroenteropancreatic neuroendocrine tumors","volume":"1","author":"Beyens","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_147","first-page":"478","article-title":"Allosteric modulation of Ras and the PI3K\/AKT\/mTOR pathway: Emerging therapeutic opportunities","volume":"16","author":"Hubbard","year":"2014","journal-title":"Front. Physiol."},{"key":"ref_148","first-page":"1084","article-title":"The PI3K\/AKT pathway in the pathogenesis of prostate cancer","volume":"1","author":"Chen","year":"2016","journal-title":"Front. Biosci."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12964-020-0531-3","article-title":"The (pro)renin receptor: A novel biomarker and potential therapeutic target for various cancers","volume":"6","author":"Wang","year":"2020","journal-title":"Cell Commun. Signal"},{"key":"ref_150","first-page":"10","article-title":"ALDH1A3 accelerates pancreatic cancer metastasis by promoting glucose metabolism","volume":"16","author":"Nie","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_151","first-page":"135","article-title":"The complexities of obesity and diabetes with the development and progression of pancreatic cancer","volume":"1815","author":"Bao","year":"2011","journal-title":"Biochim. Biophys. Acta."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.biopha.2018.10.125","article-title":"EG-VEGF silencing inhibits cell proliferation and promotes cell apoptosis in pancreatic carcinoma via PI3K\/AKT\/mTOR signaling pathway","volume":"109","author":"Yan","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"ref_153","first-page":"3102","article-title":"Tanshinone IIA can inhibit MiaPaCa2 human pancreatic cancer cells by dual blockade of the Ras\/Raf\/MEK\/ERK and PI3K\/AKT\/mTOR pathways","volume":"40","author":"Su","year":"2018","journal-title":"Oncol. Rep."},{"key":"ref_154","first-page":"2449","article-title":"Effects of aspirin on pancreatic cancer cells PANC-1 and its potential molecular mechanism","volume":"25","author":"Lin","year":"2020","journal-title":"J. Buon."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"151769","DOI":"10.1016\/j.acthis.2021.151769","article-title":"The enhancement of tetrandrine to gemcitabine-resistant PANC-1 cytochemical sensitivity involves the promotion of PI3K\/Akt\/mTOR-mediated apoptosis and AMPK-regulated autophagy","volume":"123","author":"Song","year":"2021","journal-title":"Acta. Histochem."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.bcp.2012.08.007","article-title":"Rottlerin induces autophagy which leads to apoptotic cell death through inhibition of PI3K\/Akt\/mTOR pathway in human pancreatic cancer stem cells","volume":"1","author":"Singh","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.3727\/096504018X15166223632406","article-title":"Phosphoglycerate mutase 1 (PGAM1) promotes pancreatic ductal adenocarcinoma (PDAC) metastasis by acting as a novel downstream target of the PI3K\/Akt\/mTOR pathway","volume":"23","author":"Liu","year":"2018","journal-title":"Oncol. Res."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1159\/000501829","article-title":"STK33 promotes the growth and progression of human pancreatic neuroendocrine tumour via activation of the PI3K\/AKT\/mTOR pathway","volume":"110","author":"Zhou","year":"2020","journal-title":"Neuroendocrinology"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/gutjnl-2018-316822","article-title":"Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine","volume":"68","author":"Conway","year":"2019","journal-title":"Gut"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"6911","DOI":"10.1158\/0008-5472.CAN-16-0810","article-title":"mTORC2 signaling drives the development and progression of pancreatic cancer","volume":"76","author":"Driscoll","year":"2016","journal-title":"Cancer Res."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)00141-0","article-title":"Pancreatic cancer","volume":"388","author":"Kamisawa","year":"2016","journal-title":"Lancet"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0140-6736(10)62307-0","article-title":"Pancreatic cancer","volume":"378","author":"Vincent","year":"2011","journal-title":"Lancet"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(04)15841-8","article-title":"Pancreatic cancer","volume":"363","author":"Li","year":"2004","journal-title":"Lancet"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor\u2013positive advanced breast cancer","volume":"380","author":"Ciruelos","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_165","unstructured":"(2022, July 05). FDA Approves Alpelisib for PIK3CA-Related Overgrowth Spectrum, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-alpelisib-pik3ca-related-overgrowth-spectrum."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"e13502","DOI":"10.15252\/emmm.202013502","article-title":"Pancreatic cancer intrinsic PI3K\u03b1 activity accelerates metastasis and rewires macrophage component","volume":"13","author":"Thibault","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2018.36.4_suppl.398","article-title":"Final report: A phase I trial of BYL719 in Combination with Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer","volume":"36","author":"Soares","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1158\/1078-0432.CCR-14-1814","article-title":"Phase Ib dose-escalation study of the oral Pan-PI3K inhibitor Buparlisib (BKM120) in combination with the oral MEK1\/2 inhibitor Trametinib (GSK1120212) in patients with selected advanced solid tumors PI3K inhibitor Buparlisib with MEK inhibitor Trametinib","volume":"21","author":"Bedard","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Ma, Y., Sender, S., Sekora, A., Kong, W., Bauer, P., Ameziane, N., Al-Ali, R., Krake, S., Radefeldt, M., and Weiss, F.U. (2022). The inhibitory response to PI3K\/AKT pathway inhibitors MK-2206 and Buparlisib is related to genetic differences in pancreatic ductal adenocarcinoma cell lines. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23084295"},{"key":"ref_170","unstructured":"(2022, June 15). BKM120 + mFOLFOX6 in Advanced Solid Tumors with Expansion Cohort Pancreatic Cancer. NCT01571024, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01571024."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s10637-015-0298-3","article-title":"A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors","volume":"33","author":"McRee","year":"2015","journal-title":"Investig. New Drugs"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1158\/1535-7163.763.3.7","article-title":"Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling","volume":"3","author":"Ihle","year":"2004","journal-title":"Mol. Cancer Ther."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1158\/1078-0432.CCR-12-0714","article-title":"A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-Kinase inhibitor, in patients with advanced solid tumors first-in-human trial of PX-866","volume":"18","author":"Hong","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_174","unstructured":"(2022, June 15). BAY80-6946 Open Label, Phase I Study in Patients with Advanced Cancer. NCT00962611, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00962611."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/annonc\/mdw282","article-title":"First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin\u2019s lymphomas","volume":"27","author":"Patnaik","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1158\/1535-7163.MCT-08-1200","article-title":"Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: From PI-103 through PI-540, PI-620 to the oral agent GDC-0941","volume":"8","author":"Raynaud","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1158\/1078-0432.CCR-14-0947","article-title":"First-in-human phase I study of Pictilisib (GDC-0941), a Potent Pan\u2013Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid TumorsFIH Phase I Trial of Potent and Selective Pan\u2013PI3K Inhibitor Pictilisib","volume":"21","author":"Sarker","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10637-016-0382-3","article-title":"Phase Ia\/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer","volume":"35","author":"Yamamoto","year":"2017","journal-title":"Investig. New Drugs"},{"key":"ref_179","unstructured":"(2022, June 17). Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination with Pictilisib in Patients with Locally Advanced or Metastatic Solid Tumors. NCT00996892, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00996892."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10637-019-00776-6","article-title":"Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors","volume":"38","author":"Shapiro","year":"2020","journal-title":"Investig. New. Drugs."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"103749","DOI":"10.1016\/j.critrevonc.2022.103749","article-title":"Prospects of targeting PI3K\/AKT\/mTOR pathway in pancreatic cancer","volume":"176","author":"Mortazavi","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00280-014-2397-9","article-title":"Perifosine inhibits S6K1\u2013Gli1 signaling and enhances gemcitabine-induced anti-pancreatic cancer efficiency","volume":"73","author":"Xin","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/01.coc.0000251235.46149.43","article-title":"A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma","volume":"30","author":"Marsh","year":"2007","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1200\/jco.2005.23.16_suppl.4166","article-title":"A phase II trial of perifosine as second line therapy for advanced pancreatic cancer. A study of the Princess Margaret Hospital [PMH] phase II consortium","volume":"23","author":"Hedley","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1111\/febs.15011","article-title":"Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: From mechanism to therapy","volume":"286","author":"Parkin","year":"2019","journal-title":"FEBS J."},{"key":"ref_186","unstructured":"(2022, June 18). Safety, Pharmacokinetics (PK) of AKT and MEK Combination. NCT01138085, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01138085."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00280-020-04038-8","article-title":"Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1\/MEK2 inhibitor trametinib in patients with solid tumors","volume":"85","author":"Tolcher","year":"2020","journal-title":"Cancer Chemoter. Pharmacol."},{"key":"ref_188","first-page":"9040","article-title":"Recent advance of Akt inhibitors in clinical trials","volume":"4","author":"Guo","year":"2019","journal-title":"Chemistry. Select."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2174\/1568026620666200224101808","article-title":"Akt pathway inhibitors","volume":"20","author":"Uko","year":"2020","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_190","unstructured":"(2022, June 18). A Study of the Safety and Activity of the MEK Inhibitor Given Together with the AKT Inhibitor to Patients with Multiple Myeloma or Solid Tumor Cancers. NCT01476137, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01476137."},{"key":"ref_191","unstructured":"(2022, June 20). Continuation Study of the Oral AKT Inhibitor GSK2110183. NCT01531894, Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01531894."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.toxicon.2022.06.010","article-title":"Antitumor effects of oleandrin in different types of cancers: Systematic review","volume":"216","author":"Francischini","year":"2022","journal-title":"Toxicon"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s10637-014-0190-6","article-title":"PBI-05204, a supercritical CO2 extract of Nerium oleander, inhibits growth of human pancreatic cancer via targeting the PI3K\/mTOR pathway","volume":"33","author":"Pan","year":"2015","journal-title":"Investig. New Drugs"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1177\/1534735407309623","article-title":"Autophagic cell death of human pancreatic tumor cells mediated by oleandrin, a lipid-soluble cardiac glycoside","volume":"6","author":"Newman","year":"2007","journal-title":"Integr. Cancer Ther."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1158\/1535-7163.MCT-08-1085","article-title":"Oleandrin-mediated inhibition of human tumor cell proliferation: Importance of Na, K-ATPase \u03b1 subunits as drug targetsNa, K-ATPase Composition and Oleandrin Cytotoxicity","volume":"8","author":"Yang","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1007\/s10637-014-0127-0","article-title":"First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-\u03ba\u0392 and p70s6k, in patients with advanced solid tumors","volume":"32","author":"Hong","year":"2014","journal-title":"Investig. New Drugs"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"e1446","DOI":"10.1634\/theoncologist.2020-0440","article-title":"A phase II, single-arm, open-label, bayesian adaptive efficacy and safety study of PBI-05204 in patients with stage IV metastatic pancreatic adenocarcinoma","volume":"25","author":"Roth","year":"2020","journal-title":"Oncologist"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1158\/1078-0432.CCR-10-2061","article-title":"Two drug interaction studies of Sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies two drug interaction studies of Sirolimus","volume":"17","author":"Gangadhar","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/sj.bjc.6605819","article-title":"Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer","volume":"103","author":"Tan","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.2008.18.9514","article-title":"Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer","volume":"27","author":"Wolpin","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2009.24.2669","article-title":"Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: A phase II trial","volume":"28","author":"Yao","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s00280-015-2730-y","article-title":"Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer","volume":"75","author":"Kordes","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_203","first-page":"280","article-title":"Current and future systemic treatment options in metastatic pancreatic cancer","volume":"5","author":"Arslan","year":"2014","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_204","unstructured":"(2022, June 20). Metformin Combined with Chemotherapy for Pancreatic Cancer. NCT01210911, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01210911."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1470-2045(15)00027-3","article-title":"Metformin in patients with advanced pancreatic cancer: A double-blind, randomised, placebo-controlled phase 2 trial","volume":"16","author":"Kordes","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_206","unstructured":"(2022, June 21). A Study of Metformin with or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects with Pancreatic Cancer. NCT02048384, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02048384."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.18632\/oncotarget.27586","article-title":"An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocarcinoma","volume":"11","author":"Bever","year":"2020","journal-title":"Oncotarget"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.7150\/jca.15419","article-title":"Pancreatic cancer from molecular pathways to treatment opinion","volume":"7","author":"Karanikas","year":"2016","journal-title":"J. Cancer"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3748\/wjg.v22.i2.776","article-title":"Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies","volume":"22","author":"Matsuoka","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_210","unstructured":"(2022, June 21). A Safety and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer. NCT01028495, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01028495."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1200\/jco.2010.28.15_suppl.3009","article-title":"First-in-class phase I trial of a selective Akt inhibitor, MK2206 (MK), evaluating alternate day (QOD) and once weekly (QW) doses in advanced cancer patients (pts) with evidence of target modulation and antitumor activity","volume":"28","author":"Yap","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_212","first-page":"1999","article-title":"Akt inhibitor MK2206 reduces pancreatic cancer cell viability and increases the efficacy of gemcitabine","volume":"19","author":"Wang","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1158\/1535-7163.MCT-15-0028","article-title":"Combined inhibition of cyclin-dependent kinases (Dinaciclib) and AKT (MK-2206) blocks pancreatic tumor growth and metastases in patient-derived xenograft models","volume":"14","author":"Hu","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/cts.12802","article-title":"A Phase I Study of Dinaciclib in Combination With MK-2206 in Patients with Advanced Pancreatic Cancer","volume":"13","author":"Murphy","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s10637-010-9479-2","article-title":"Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT","volume":"29","author":"Garrett","year":"2011","journal-title":"Investig. New Drugs"},{"key":"ref_216","first-page":"4599","article-title":"Triciribine phosphate monohydrate, an AKT inhibitor, enhances gemcitabine activity in pancreatic cancer cells","volume":"35","author":"Kim","year":"2015","journal-title":"Anticancer Res."},{"key":"ref_217","doi-asserted-by":"crossref","unstructured":"Javle, M.M., Shroff, R.T., Xiong, H., Varadhachary, G.A., Fogelman, D., Reddy, S.A., Davis, D., Zhang, Y., Wolff, R.A., and Abbruzzese, J.L. (2010). Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: Results of two phase II studies. BMC Cancer, 10.","DOI":"10.1186\/1471-2407-10-368"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s11523-018-0605-y","article-title":"Gemcitabine combined with the mTOR inhibitor temsirolimus in patients with locally advanced or metastatic pancreatic cancer. A hellenic cooperative oncology group phase i\/II study","volume":"13","author":"Karavasilis","year":"2018","journal-title":"Target. Oncol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.clon.2013.02.005","article-title":"A phase I trial of oral ridaforolimus (AP23573; MK-8669) in combination with bevacizumab for patients with advanced cancers","volume":"25","author":"Nemunaitis","year":"2013","journal-title":"Clin Oncol."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1158\/1078-0432.CCR-14-2422","article-title":"First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1\/2 Inhibitor AZD2014Phase I Study of AZD2014","volume":"21","author":"Basu","year":"2015","journal-title":"Clin. Cancer. Res"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s10637-015-0241-7","article-title":"A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer","volume":"33","author":"Azaro","year":"2015","journal-title":"Investig. New Drugs"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/jcb.23405","article-title":"The efficacy of a novel, dual PI3K\/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer","volume":"113","author":"Awasthi","year":"2012","journal-title":"J. Cell. Biochem."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1158\/1535-7163.MCT-14-0669","article-title":"Dual PI3K\/mTOR inhibitors induce rapid overactivation of the MEK\/ERK pathway in human pancreatic cancer cells through suppression of mTORC2","volume":"14","author":"Soares","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_224","first-page":"1997","article-title":"ERK\/MAPK signalling pathway and tumorigenesis","volume":"19","author":"Guo","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"32039","DOI":"10.18632\/oncotarget.5055","article-title":"PI3K\/AKT\/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth","volume":"6","author":"Sharma","year":"2015","journal-title":"Oncotarget"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1021\/ml1000307","article-title":"Discovery of NVP-LDE225, a potent and selective smoothened antagonist","volume":"1","author":"Pan","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s10637-018-0614-9","article-title":"A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM\/2012\u201312 (EDALINE) study","volume":"37","author":"Jimenez","year":"2019","journal-title":"Investig. New Drugs"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1158\/1535-7163.MCT-18-0354","article-title":"Tumor priming by SMO inhibition enhances antibody delivery and efficacy in a pancreatic ductal adenocarcinoma model","volume":"18","author":"Wang","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/neuonc\/nov083","article-title":"Phase I dose-escalation study of the PI3K\/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma","volume":"17","author":"Wen","year":"2015","journal-title":"Neuro-Oncol."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1038\/s41416-018-0322-4","article-title":"A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K\/MTOR inhibitor voxtalisib in patients with advanced solid tumours","volume":"119","author":"Schram","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1158\/1078-0432.CCR-13-2403","article-title":"Phase I safety, Pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K\/mTOR inhibitor in patients with advanced solid tumors","volume":"20","author":"Papadopoulos","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s11523-017-0530-5","article-title":"A multi-arm phase I study of the PI3K\/mTOR inhibitors PF-04691502 and gedatolisib (PF-05212384) plus irinotecan or the MEK inhibitor PD-0325901 in advanced cancer","volume":"12","author":"Wainberg","year":"2017","journal-title":"Target Oncol."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1016\/j.ejca.2012.06.027","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K\/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies","volume":"48","author":"Mahadevan","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3389\/fonc.2014.00064","article-title":"Targeting PI3K\/Akt\/mTOR signaling in cancer","volume":"4","author":"Porta","year":"2014","journal-title":"Front. Oncol."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): A randomised, placebo-controlled, phase 3 study","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/jjco\/hys123","article-title":"Everolimus for advanced pancreatic neuroendocrine tumours: A subgroup analysis evaluating Japanese patients in the RADIANT-3 trial","volume":"42","author":"Ito","year":"2012","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1158\/1538-7445.AM2022-4027","article-title":"Dual MEK and AKT inhibition suppresses pancreatic cancer growth and migration","volume":"82","author":"Jack","year":"2022","journal-title":"Cancer Res."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1158\/1078-0432.CCR-15-1665","article-title":"First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies","volume":"22","author":"Munster","year":"2016","journal-title":"Clin. Cancer Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/17\/10132\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:23:15Z","timestamp":1760142195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/17\/10132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,4]]},"references-count":238,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["ijms231710132"],"URL":"https:\/\/doi.org\/10.3390\/ijms231710132","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,4]]}}}